Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZW4864 (free base) is an orally active and selective β catenin/B-Cell lymphoma 9 protein protein interaction ( β catenin/BCL9 PPI ) inhibitor. ZW4864 (free base) inhibits β catenin/BCL9 PPI with a K i value of 0.76 μM and an IC 50 value of 0.87 μM [1]. ZW4864 (free base) shows good pharmacokinetic properties.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 163.00 | |
5 mg | In stock | $ 413.00 | |
10 mg | In stock | $ 618.00 | |
25 mg | In stock | $ 985.00 | |
50 mg | In stock | $ 1,330.00 | |
100 mg | In stock | $ 1,790.00 | |
500 mg | In stock | $ 3,590.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 455.00 |
Description | ZW4864 (free base) is an orally active and selective β catenin/B-Cell lymphoma 9 protein protein interaction ( β catenin/BCL9 PPI ) inhibitor. ZW4864 (free base) inhibits β catenin/BCL9 PPI with a K i value of 0.76 μM and an IC 50 value of 0.87 μM [1]. ZW4864 (free base) shows good pharmacokinetic properties. |
In vitro | ZW4864 (10~40 μM; free base) demonstrates a multifaceted inhibitory effect on β-catenin signaling pathways in various cancer cell lines. Over 24 hours, it diminishes Axin2 and cyclin D1 protein levels in SW480 and MDA-MB-231 cells, and selectively induces apoptosis in triple-negative breast cancer cells (MDA-MB231, MDA-MB-468) with hyperactive β-catenin, sparing normal MCF10A cells, over 72 hours. It also decreases the transcription of β-catenin target genes without affecting HPRT expression, indicating specificity in its action. By binding to β-catenin, ZW4864 disrupts its interaction with BCL9 but not with E-cadherin, thereby selectively targeting β-catenin's oncogenic activity. This compound efficaciously suppresses β-catenin-dependent signaling and invasiveness of cancer cells, as well as TOPFlash luciferase activity in a dose-dependent manner, showing particular potency with IC50 values ranging from 6.3 to 11 μM across different cell lines. Collectively, these findings underscore ZW4864's potential as a targeted therapeutic agent against β-catenin-dependent malignancies. |
In vivo | Administered orally at a dosage of 20 mg/kg, ZW4864 (free base) displays favorable pharmacokinetic properties, achieving an oral bioavailability of 83% in C57BL/6 mice [1]. At a higher dosage of 90 mg/kg, also administered orally, it demonstrates the ability to influence tumor growth in mice [1]. Additionally, ZW4864 (free base) effectively inhibits β-catenin target gene expression in a patient-derived xenograft mouse model, further indicating its potential therapeutic benefits [1]. |
Molecular Weight | 570.72 |
Formula | C33H42N6O3 |
CAS No. | 2632259-92-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (157.7 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ZW4864 free base 2632259-92-6 Cytoskeletal Signaling Stem Cells Wnt/beta-catenin ZW-4864 ZW 4864 ZW4864 inhibitor inhibit